Drug Trial Radar · NCT06982924
A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.
Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
136
Planned (sponsor's estimate)
Start
Jun 30, 2025
Primary completion
Dec 30, 2026
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Shanghai Chest HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Innovent Biologics (Suzhou) Co. Ltd.
- First posted
- May 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, controlled Phase II clinical study on the efficacy and safety of the combination of limertinib and bevacizumab versus limertinib monotherapy as first - line treatment for locally advanced or recurrent metastatic non - squamous NSCLC with EGFR mutations and high PD-L1 expression.
Conditions
- EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
- PD-L1 Positive
Interventions
Limertinib+bevacizumabDrug
The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive the combination of Limertinib with bevacizuma in first-line treatment
LimertinibDrug
The advanced or metastatic non-small cell lung cancer patients with EGFR mutation and high PD-L1 expression will receive Limertinib in first-line treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: About 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.